This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas.
Findings from RedirecTT-1 show responses across different dose levels of talquetamab/teclistamab among those with multiple myeloma.
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
PHILADELPHIA (January 31, 2025) — Eric Goodlev, MD, an Associate Professor in the Supportive Oncology and Palliative Care Program at Fox Chase Cancer Center, was recently named…
Linde Morsink, MD, this year’s recipient of the Editorial Award for Clinical Research, previews her lecture on using post transplantation cyclophosphamide (PTCy) in combination with…
This cross-sectional study evaluates how cardiovascular hospitalization rates compare in the US and Denmark, including differences by income level.
Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.
A bipartisan group of senators reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, which would expand Medicare coverage to include certain FDA-approved MCED…
Authors: Bhaavna Yalavarthi1 and Grace Collins2 In 2011, Friends published a study in Health Affairs that challenged the prevailing narrative of the time, which suggested…
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
This report on nutrition among patients with cancer highlights current and potential roles for oncology nurses in incorporating nutrition care into cancer care.
